Literature DB >> 29276252

BACE Inhibitors and Tau Protein Targeting Drugs in Prevention of Alzheimer's Disease.

Jonathan Orf1, Scot Walker2.   

Abstract

Alzheimer's disease (AD) is a common disease in the United States with almost 10% of people older than 65 suffering from the disease. A few drugs provide some improvement in mental function in mild-to-moderate disease, but no treatments are available to prevent the development of AD. Two new classes of drugs being investigated for the treatment or prevention of AD include drugs to decrease beta amyloid accumulation and Tau protein aggregation inhibitors. After disappointing results for treatment of AD, both classes are being tested in prevention trials.

Entities:  

Keywords:  formulary management/P&T; investigational drugs; neurology

Year:  2017        PMID: 29276252      PMCID: PMC5735767          DOI: 10.1177/0018578717735642

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  4 in total

Review 1.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

2.  Treatment of Alzheimer disease.

Authors:  Bradford T Winslow; Mary K Onysko; Christian M Stob; Kathleen A Hazlewood
Journal:  Am Fam Physician       Date:  2011-06-15       Impact factor: 3.292

Review 3.  Alzheimer's disease.

Authors:  Vanessa J De-Paula; Marcia Radanovic; Breno S Diniz; Orestes V Forlenza
Journal:  Subcell Biochem       Date:  2012

Review 4.  Alzheimer's disease and the amyloid-beta peptide.

Authors:  M Paul Murphy; Harry LeVine
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.